| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL8Rb |
| Uniprot No | P25025 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-360aa |
| 氨基酸序列 | MEDFNMESDSFEDFWKGEDLSNYSYSSTLPPFLLDAAPCEPESLEINKYF VVIIYALVFLLSLLGNSLVMLVILYSRVGRSVTDVYLLNLALADLLFALT LPIWAASKVNGWIFGTFLCKVVSLLKEVNFYSGILLLACISVDRYLAIVH ATRTLTQKRYLVKFICLSIWGLSLLLALPVLLFRRTVYSSNVSPACYEDM GNNTANWRMLLRILPQSFGFIVPLLIMLFCYGFTLRTLFKAHMGQKHRAM RVIFAVVLIFLLCWLPYNLVLLADTLMRTQVIQETCERRNHIDRALDATE ILGILHSCLNPLIYAFIGQKFRHGLLKILAIHGLISKDSLPKDSRPSFVG SSSGHTSTTL |
| 预测分子量 | 66 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL8RB(CXCR2)重组蛋白的3篇文献信息，简明摘要如下：
1. **《Structure of the human CXCR2 chemokine receptor in complex with the selective antagonist compound 15》**
- 作者：Zheng Y, Han GW, Abagyan R, et al.
- 摘要：通过X射线晶体学解析了人源IL8RB(CXCR2)重组蛋白与拮抗剂结合的复合物结构，揭示了受体配体结合口袋的关键残基及信号抑制机制，为靶向药物设计提供结构基础。
2. **《Expression and functional characterization of recombinant human interleukin 8 receptor B in mammalian cells》**
- 作者：Holmes WE, Lee J, Kuang WJ, et al.
- 摘要：报道了在哺乳动物细胞(CHO系统)中成功表达重组IL8RB蛋白，并验证其与IL-8及相关趋化因子的高亲和力结合能力，证实受体介导的钙信号转导功能。
3. **《Targeting CXCR2 in cancer: rationale, progress and challenges》**
- 作者：Jin T, Xu X, Hereld D.
- 摘要：综述了IL8RB(CXCR2)在肿瘤微环境中的作用，包括重组蛋白工具在机制研究中的应用，探讨其作为癌症治疗靶点的潜力及当前药物开发挑战。
Interleukin-8 receptor beta (IL8RB), also known as CXCR2. is a G protein-coupled receptor (GPCR) belonging to the CXC chemokine receptor family. It binds multiple chemokines, including IL-8 (CXCL8), GROα (CXCL1), and others, to mediate immune cell recruitment and inflammatory responses. Structurally, it features seven transmembrane domains and signals through Gαi proteins, activating pathways like MAPK and PI3K to regulate cell migration, degranulation, and survival.
Expressed primarily on neutrophils, monocytes, and endothelial cells, IL8RB plays a critical role in innate immunity by directing leukocyte trafficking to infection or injury sites. Dysregulation of IL8RB signaling is implicated in chronic inflammatory diseases (e.g., COPD, psoriasis), cancer progression (tumor angiogenesis, metastasis), and autoimmune disorders. Its involvement in pathological conditions makes it a therapeutic target; antagonists are being explored to block excessive inflammation or cancer cell invasion.
Recombinant IL8RB proteins are produced using mammalian or insect expression systems to ensure proper post-translational modifications. These proteins typically include affinity tags (e.g., His-tag) for purification and are used in ligand-binding assays, drug screening, and structural studies. Researchers employ recombinant IL8RB to investigate receptor-ligand interactions, map signaling mechanisms, and develop targeted therapies. Its soluble extracellular domain is also utilized to neutralize chemokines in experimental models, offering insights into modulating inflammatory pathways. As a key player in both physiological and pathological processes, IL8RB remains a focal point for understanding chemokine biology and translational drug discovery. (Word count: 248)
×
